Review



fgfr inhibitor clinical trial assay (cta)  (Janssen)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Janssen fgfr inhibitor clinical trial assay (cta)
    Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 <t>FGFR+</t> patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; <t>CTA,</t> clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.
    Fgfr Inhibitor Clinical Trial Assay (Cta), supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fgfr inhibitor clinical trial assay (cta)/product/Janssen
    Average 90 stars, based on 1 article reviews
    fgfr inhibitor clinical trial assay (cta) - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment"

    Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

    Journal: The Journal of Pathology: Clinical Research

    doi: 10.1002/cjp2.163

    Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 FGFR+ patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; CTA, clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.
    Figure Legend Snippet: Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 FGFR+ patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; CTA, clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.

    Techniques Used: Selection, Diagnostic Assay

    Concordance analysis for CDx and CTA (reference) FGFR gene mutation screening methods
    Figure Legend Snippet: Concordance analysis for CDx and CTA (reference) FGFR gene mutation screening methods

    Techniques Used: Mutagenesis

    Investigator‐assessed ORR in erdafitinib‐treated patients who were FGFR+ by both CDx and CTA assays
    Figure Legend Snippet: Investigator‐assessed ORR in erdafitinib‐treated patients who were FGFR+ by both CDx and CTA assays

    Techniques Used:



    Similar Products

    fgfr inhibitor clinical trial assay (cta)  (Almac Inc)
    90
    Almac Inc fgfr inhibitor clinical trial assay (cta)
    Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 <t>FGFR+</t> patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; <t>CTA,</t> clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.
    Fgfr Inhibitor Clinical Trial Assay (Cta), supplied by Almac Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fgfr inhibitor clinical trial assay (cta)/product/Almac Inc
    Average 90 stars, based on 1 article reviews
    fgfr inhibitor clinical trial assay (cta) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    fgfr inhibitor clinical trial assay (cta)  (Janssen)
    90
    Janssen fgfr inhibitor clinical trial assay (cta)
    Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 <t>FGFR+</t> patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; <t>CTA,</t> clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.
    Fgfr Inhibitor Clinical Trial Assay (Cta), supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fgfr inhibitor clinical trial assay (cta)/product/Janssen
    Average 90 stars, based on 1 article reviews
    fgfr inhibitor clinical trial assay (cta) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 FGFR+ patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; CTA, clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.

    Journal: The Journal of Pathology: Clinical Research

    Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

    doi: 10.1002/cjp2.163

    Figure Lengend Snippet: Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 FGFR+ patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; CTA, clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.

    Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

    Techniques: Selection, Diagnostic Assay

    Concordance analysis for CDx and CTA (reference) FGFR gene mutation screening methods

    Journal: The Journal of Pathology: Clinical Research

    Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

    doi: 10.1002/cjp2.163

    Figure Lengend Snippet: Concordance analysis for CDx and CTA (reference) FGFR gene mutation screening methods

    Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

    Techniques: Mutagenesis

    Investigator‐assessed ORR in erdafitinib‐treated patients who were FGFR+ by both CDx and CTA assays

    Journal: The Journal of Pathology: Clinical Research

    Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

    doi: 10.1002/cjp2.163

    Figure Lengend Snippet: Investigator‐assessed ORR in erdafitinib‐treated patients who were FGFR+ by both CDx and CTA assays

    Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

    Techniques:

    Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 FGFR+ patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; CTA, clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.

    Journal: The Journal of Pathology: Clinical Research

    Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

    doi: 10.1002/cjp2.163

    Figure Lengend Snippet: Study design and sample selection. *Includes 1 untreated patient in regimen 3. ** n = 600 samples were not eligible for the bridging study (reasons: received before November 28, 2015, no consent for bridging testing, insufficient samples or passing sample store limit). † Includes 1 FGFR+ patient who was not treated but was eligible for the bridging study. ‡ 320 patients were randomly selected and then 120 patients were removed due to a change in the selecting protocol. CDx, companion diagnostic assay; CTA, clinical trial assay; FGFR, fibroblast growth factor receptor; ORR, objective response rate.

    Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

    Techniques: Selection, Diagnostic Assay

    Concordance analysis for CDx and CTA (reference) FGFR gene mutation screening methods

    Journal: The Journal of Pathology: Clinical Research

    Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

    doi: 10.1002/cjp2.163

    Figure Lengend Snippet: Concordance analysis for CDx and CTA (reference) FGFR gene mutation screening methods

    Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

    Techniques: Mutagenesis

    Investigator‐assessed ORR in erdafitinib‐treated patients who were FGFR+ by both CDx and CTA assays

    Journal: The Journal of Pathology: Clinical Research

    Article Title: Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

    doi: 10.1002/cjp2.163

    Figure Lengend Snippet: Investigator‐assessed ORR in erdafitinib‐treated patients who were FGFR+ by both CDx and CTA assays

    Article Snippet: The FGFR inhibitor Clinical Trial Assay (CTA), a RT‐PCR assay developed by Janssen, USA, and performed by Almac Diagnostics (Craigavon, UK) was used to determine the FGFR alteration status in patients enrolled for the erdafitinib phase 2 study.

    Techniques: